Search

Your search keyword '"Michael Meister"' showing total 26 results
Start Over Author "Michael Meister" Publisher georg thieme verlag kg
26 results on '"Michael Meister"'

1. Clinical and molecular profile of de novo vs. secondary EGFR mutated metastatic non-small-cell lung cancer

Author

M. Faehling, N. Magios, J. Kuon, Albrecht Stenzinger, Daniel Kazdal, Fjf Herth, Volker Endris, Michael Meister, Thomas Muley, Michael Thomas, Stefan Rieken, Helge Bischoff, Tilmann Bochtler, Harland S. Winter, Martina Kirchner, Anna-Lena Volckmar, Farastuk Bozorgmehr, Petros Christopoulos, C.P. Heussel, and J. Budczies

Subjects
business.industry, Cancer research, Medicine, Molecular Profile, Non small cell, business, Lung cancer, medicine.disease
Published
2020
Full Text
View/download PDF

4. TP53 status conversion defines an unfavourable patient subset with inferior overall survival in ALK+ lung adenocarcinoma

Author

Michael Thomas, CP Heußel, Petros Christopoulos, Felix Lasitschka, Stefan Rieken, Volker Endris, Martina Kirchner, M. Elsayed, Michael Meister, Peter Schirmacher, Simon J. Ogrodnik, Steffen Dietz, Thomas Muley, Tomasz Zemojtel, Holger Sültmann, Anna-Lena Volckmar, Helge Bischoff, and Albrecht Stenzinger

Subjects
Oncology, medicine.medical_specialty, Lung, medicine.anatomical_structure, business.industry, Internal medicine, medicine, Overall survival, Adenocarcinoma, medicine.disease, business
Published
2019
Full Text
View/download PDF

5. Clinical predoctors of immune checkpoint inhibitor efficacy in non-small cell lung cancer

Author

Stefan Rieken, S. Liersch, Helge Bischoff, Fjf Herth, Olaf Neumann, CP Heußel, A. Stenzinger, Petros Christopoulos, Harland S. Winter, J. Kuon, T Muley, J. Kohlhäufl, Michael Meister, Felix Lasitschka, Marc A. Schneider, Farastuk Bozorgmehr, and Michael Thomas

Subjects
business.industry, Immune checkpoint inhibitors, medicine, Cancer research, Non small cell, Lung cancer, medicine.disease, business
Published
2019
Full Text
View/download PDF

6. Frequency and clinical impact of atypical EGFR mutations in lung adenocarcinoma

Author

Michael Meister, Petros Christopoulos, Martina Kirchner, Anna-Lena Volckmar, Thomas Muley, N. Magios, Farastuk Bozorgmehr, Michael Thomas, Peter Schirmacher, Helge Bischoff, CP Heußel, A. Stenzinger, Harland S. Winter, Felix Lasitschka, Fjf Herth, and Volker Endris

Subjects
Lung, medicine.anatomical_structure, Egfr mutation, business.industry, Cancer research, medicine, Adenocarcinoma, medicine.disease, business
Published
2019
Full Text
View/download PDF

8. Peripheral T-cell repertoire alterations are common and affect outcome in large cell neuroendocrine lung carcinoma

Author

Christian Grohé, Michael Thomas, Joachim von Pawel, Michael Meister, Walburga Engel-Riedel, Helge Bischoff, Philipp A. Schnabel, Thomas Muley, Petros Christopoulos, Volker Baum, Monika Serke, Farastuk Bozorgmehr, Marc A. Schneider, and C. Kropf-Sanchen

Subjects
Pulmonary and Respiratory Medicine, Lung, medicine.anatomical_structure, T cell repertoire, business.industry, Large cell, Cancer research, Carcinoma, Medicine, business, Affect (psychology), medicine.disease, Peripheral
Published
2018
Full Text
View/download PDF

9. An Institutional Study on Thymomas and Thymic Carcinomas: Experience in 77 Patients

Author

Michael Meister, Peter Schirmacher, Esther Herpel, Joachim Pfannschmidt, C Klein, Philipp A. Schnabel, H. Dienemann, Ralf J. Rieker, and Thomas Muley

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Thymoma, medicine.medical_treatment, Severity of Illness Index, Diagnosis, Differential, Hospitals, University, Severity of illness, Humans, Medicine, Survival rate, Thymic carcinoma, Aged, Neoplasm Staging, Retrospective Studies, Chemotherapy, business.industry, Carcinoma, Histology, Retrospective cohort study, Thymus Neoplasms, Middle Aged, Prognosis, Thymectomy, medicine.disease, Surgery, Cardiothoracic surgery, Female, Cardiology and Cardiovascular Medicine, business, Follow-Up Studies
Abstract

Background Thymomas and thymic carcinomas are rare tumors of the anterior mediastinum. A WHO classification was introduced in 1999, which has been updated in 2004. Meanwhile, several retrospective studies have been carried out which have shown the prognostic significance of this classification together with Masaoka's staging system and the extent of surgery. Patients and methods Between 1983 and 2000, 77 patients (37 male, 40 female) underwent resection of thymomas and thymic carcinomas in our institution. Complete resection was achieved in 57 patients. The median follow-up was 72.6 months. Results The overall 5-year survival rate was 71.4 %. The factors "histology" and "extent of resection" had the most important impact on survival. However, even among the patients with complete resection, 12 of them suffered a relapse. Among this patient group, the most important factors for disease-free survival were "tumor stage" and "histology". Patients with an incomplete resection had a 5-year survival rate of only 29 % in spite of adjuvant radiation and/or chemotherapy. Due to the high rate of relapse, the poor survival rate found in incompletely resected patients as well as the failure of classical chemotherapy regimens, especially in type B2 and type B3 thymomas and thymic carcinomas, the search for new chemotherapeutic schemes is mandatory. Conclusion Our study shows that there are still encouraging therapeutic options for thymomas and thymic carinomas. Type B2, type B3 thymomas and thymic carcinomas have worse outcomes in spite of adjuvant chemo- and radiotherapies. Especially in patients with incomplete surgical resection the outcome remains poor.

Published
2008
Full Text
View/download PDF

11. Dysregulation of epithelial miR-148b contributes to goblet cell metaplasia, inflammation and alveolar damage in cystic fibrosis lung disease

Author

Catherine M. Greene, Martina U. Muckenthaler, Raman Agrawal, Thomas Muley, Michael Meister, Sandro Altamura, Marcus A. Mall, Scott H. Randell, Burkhard Tümmler, and F Stanke

Subjects
Pulmonary and Respiratory Medicine, Goblet cell, Pathology, medicine.medical_specialty, business.industry, Inflammation, medicine.disease, Cystic fibrosis, medicine.anatomical_structure, Lung disease, Metaplasia, medicine, medicine.symptom, Diffuse alveolar damage, business, Mir 148b
Published
2015
Full Text
View/download PDF

12. The Pregnancy Associated Endometrial Protein Glycodelin and its Potential as a Biomarker for Malignant Pleural Mesothelioma

Author

Michael Thomas, Marc A Schneider, Michael Meister, Fjf Herth, T Muley, Arne Warth, and H. Dienemann

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Pregnancy, Glycodelin, Pleural mesothelioma, business.industry, Internal medicine, medicine, Biomarker (medicine), business, medicine.disease
Published
2015
Full Text
View/download PDF

13. The Lung Biobank Heidelberg – A 15 Years old Basis for Lung Research

Author

Michael Meister, Arne Warth, Marc A Schneider, and T Muley

Subjects
Pulmonary and Respiratory Medicine, COPD, Pathology, medicine.medical_specialty, Tissue microarray, Lung, business.industry, Colorectal cancer, Cancer, respiratory system, medicine.disease, respiratory tract diseases, medicine.anatomical_structure, Tissue bank, medicine, Mesothelioma, Lung cancer, business
Abstract

The lung research specimen biobank located at the Thoraxklinik Heidelberg (TK-HD) is an accredited subsidiary (DAP-IS-4153.04 according to DIN EN ISO/IEC 17020) of the National Center for Tumor Diseases Heidelberg (NCT), which is integrated into the BioMaterialBank Heidelberg (BMBH). The NCT Tissue Bank is registered with the German Technology and Method Platform for Medical Research Networks (TMF) and the European Biobanking and Biomolecular Resources Research Infrastructure (BBMRI). Each year about 400 – 500 new tissue specimens and around 1000 new blood samples are collected with high quality using standard operating procedures. About two thirds of tissue samples are derived from lung cancer patients (tumor tissue plus matched normal lung tissue, lymph nodes). In addition, tissue of other thoracic malignancies (carcinoids, mesothelioma, thymoma, lung sarcomas), metastatic cancer to the lung (colorectal carcinoma, renal cell carcinoma etc.), and to a lesser extent benign lung diseases (hamartomas, interstitial lung diseases, COPD, pneumothorax) are collected. Currently the tissue bank comprises tissue sample with several aliquots from 4700 patients. There are 68% lung cancer patients, 2% lung cancer recurrences, 14% lung metastases from extrathoracic cancers, 2% carcinoids, 2% mesotheliomas, 8% benign lung diseases and 4% various diseases. In addition, several aliquots from more than 8800 blood samplings of patients with various lung diseases are processed and stored under standardized conditions. The samples can be connected to highly annotated clinical data. The lung biobank also provides services for nucleic acid extraction, production of specific tissue microarrays and for primary cell culture. High quality samples are an indispensable prerequisite for adequate research. The expertise of the Lung Biobank Heidelberg is acknowledged worldwide and therefore involved in several national and international studies and consortia i.e. the German Lung Research Centre (DZL), Canceralia, LungSys, ETOP Lungscape and The Cancer Genome Atlas (TCGA) Project. *Presenting author

Published
2015
Full Text
View/download PDF

15. Transcriptome analysis in endobronchial epithelial lining fluid compared to bronchoalveolar lavage in idiopathic pulmonary fibrosis

Author

Nicolas Kahn, Michael Meister, Martin Granzow, Michael Kreuter, T Muley, and Fjf Herth

Subjects
Pulmonary and Respiratory Medicine, Transcriptome, Pathology, medicine.medical_specialty, Idiopathic pulmonary fibrosis, Bronchoalveolar lavage, medicine.diagnostic_test, business.industry, Epithelial lining fluid, medicine, medicine.disease, business
Published
2015
Full Text
View/download PDF

17. EML4-ALK fusion variant V3 confers early treatment failure with first and second generation ALK TKI

Author

Helge Bischoff, CP Heußel, Ivo Buchhalter, Michael Thomas, Arne Warth, Farastuk Bozorgmehr, Martina Kirchner, Albrecht Stenzinger, Peter Schirmacher, Thomas Muley, Petros Christopoulos, M. Elsayed, Juergen R. Fischer, Fjf Herth, Volker Endris, Michael Meister, Martin E. Eichhorn, and Roland Penzel

Subjects
Pulmonary and Respiratory Medicine, Fusion, business.industry, Cancer research, Medicine, business, Treatment failure
Published
2018
Full Text
View/download PDF

19. Silencing of miR-148b ameliorates cystic fibrosis-like lung diseases in βENaC-overexpressing mice

Author

S Altamura, Catherine M. Greene, F Stanke, Marcus A. Mall, Thomas Muley, Burkhard Tümmler, MU Muckenthaler, M. Castoldi, Michael Meister, and Raman Agrawal

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, Lung, medicine.anatomical_structure, business.industry, medicine, Gene silencing, medicine.disease, business, Cystic fibrosis, Mir 148b
Published
2014
Full Text
View/download PDF

20. Circulating microRNAs associated with early relapse in early-stage NSCLC

Author

Stephan Gade, Ruprecht Kuner, Marc Johannes, Michael Meister, Hendrik Dienemann, Thomas Muley, Holger Sültmann, Jan C. Brase, Fjf Herth, and S Kaduthanam

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Circulating MicroRNA, Pathology, Internal medicine, medicine, Early Relapse, Stage (cooking), Biology
Published
2012
Full Text
View/download PDF

23. Stromal Cells Derived from Non-Small Cell Lung Cancer and Normal Lung Tissue Display Mesenchymal Stem Cell Characteristics and Differ in Their Gene Expression Profiles and Functional Behaviour

Author

Ruprecht Kuner, Hendrik Dienemann, Michael Meister, V. Eckstein, Martin Granzow, Fjf Herth, A. D. Ho, Michael Thomas, A. Jauch, Hans Hoffmann, Sandra Gottschling, and Thomas Muley

Subjects
Pulmonary and Respiratory Medicine, Stromal cell, Normal lung, Cancer stem cell, Gene expression, Mesenchymal stem cell, Cancer research, medicine, Non small cell, Biology, Lung cancer, medicine.disease, Adult stem cell
Published
2009
Full Text
View/download PDF

24. The Individuality of Tumour-Stroma Interaction in Non-Small Cell Lung Cancer: Insights from Funtional and Molecular Analysis

Author

Sandra Gottschling, Hendrik Dienemann, E. Chang Xu, V. Eckstein, Michael Thomas, Fjf Herth, A. Jauch, Hans Hoffmann, Martin Granzow, Thomas Muley, Ruprecht Kuner, Michael Meister, and A. D. Ho

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Internal medicine, Tumour stroma, medicine, Cancer research, Non small cell, Biology, Lung cancer, medicine.disease, Molecular analysis
Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results